Trump's FDA Pick: A Recipe for Regulatory Chaos The appointment of Dr.
Heidi Overton as the new head of the Food and Drug Administration (FDA) has sent shockwaves through the medical and pharmaceutical communities, marking her transition from policy advisor to regulatory decision maker with significant implications for the agency's priorities and the public it serves.
Overton's confirmation is likely to be met with intense scrutiny, particularly given her vocal opposition to abortion pills and her involvement in some of President Trump's most contentious health initiatives.